Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Posts Higher Q2 Revenues, Narrowed Loss

NEW YORK, Aug. 13 - Third Wave Technologies today reported increased second-quarter revenues atop narrowed losses, as a tighter R&D budget reflected the company's continued efforts to cut costs.


For the period ended June 30, Third Wave reported $9.6 million in total revenue compared with $8.7 million in the year-ago period. The increase was due primarily to stronger product sales, which jumped to $9 million in the current quarter from $7.8 million one year ago.


R&D spending, which was trimmed to $3.6 million in the second quarter 2002 from $4 million in the same period last year, led the cut in total second-quarter operating expenses, according to Third Wave.


As a result of the belt-tightening, net loss in the quarter narrowed to $6.1 million, or $.16 per share, from $6.6 million, or $.17 per share, year over year.


Third Wave said it had roughly $60 million in cash, cash equivalents, and short-term investments as of June 30.


The company has scheduled an investor web cast today at 10:00 a.m. Eastern time.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.